Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sunitinib + cisplatin + gemcitabine
- Development stage
- Phase 2
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of sunitinib (a multitargeted tyrosine kinase inhibitor), cisplatin (a platinum-based chemotherapy agent), and gemcitabine (a nucleoside analog). This combination has been investigated in clinical trials for the treatment of advanced non-small cell lung cancer (NSCLC) and metastatic urothelial cancer (mUC). The regimen combines targeted therapy with conventional chemotherapy, targeting both angiogenesis pathways and cancer cell division.
- Other names
- gemcitabine hydrochloridecis-diamminedichloroplatinum(II)sunitinib malate
02
Targets
FLT3 (Fms related receptor tyrosine kinase 3)KIT (c-KIT proto-oncogene receptor tyrosine kinase)MET (Mesenchymal-epithelial transition factor receptor)PDGFR (PDGFR family)RET (Rearranged during transfection receptor tyrosine kinase)VEGFR (VEGFR family)DNA
Beyond the preview
Go deeper on sunitinib + cisplatin + gemcitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sunitinib + cisplatin + gemcitabine.